Nelson, B.
Amminger, G. P.
Yuen, H. P.
Markulev, C.
Lavoie, S.
Schäfer, M. R.
Hartmann, J. A.
Mossaheb, N.
Schlögelhofer, M.
Smesny, S.
Hickie, I. B.
Berger, G.
Chen, E. Y. H.
de Haan, L.
Nieman, D. H.
Nordentoft, M.
Riecher-Rössler, A.
Verma, S.
Thompson, A.
Yung, A. R.
McGorry, P. D.
Article History
Received: 19 March 2018
Revised: 4 May 2018
Accepted: 11 May 2018
First Online: 25 June 2018
Competing interests
: Dr. McGorry reported receiving grant funding from National Alliance for Research on Schizophrenia and Depression and unrestricted research funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche, and the Lundbeck Institute. Drs. Nelson, Hickie, Yung, and Amminger have received National Health and Medical Research Council (NHMRC) funding. The remaining authors declare no competing interests.